Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
PRICE
Prev Close
27.21
Open
27.08
Day Range26.27 – 27.16
26.27
27.16
52W Range13.60 – 29.75
13.60
29.75
80% of range
50-Day MA
24.21(+9.8%)
200-Day MA
24.41(+8.8%)
VOLUME & SIZE
Avg Volume
599.1K
FUNDAMENTALS
P/E (TTM)
-19.4x
Not profitable
EPS (TTM)
—
Div Yield (TTM)
No dividend
Beta
0.98
Market-like
TECHNICAL
RSI (14)
63
Bullish momentum
ZYME News
About
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.